Oxford Brain Diagnostics (OBD) is preparing to launch its groundbreaking technology for the early diagnosis of dementia across the UK and US healthcare markets, following a wave of key regulatory approvals that mark a major milestone in the company’s growth.
Backed by growth capital investor BGF, the Oxford-based medtech firm will begin commercial deployment of its patented Cortical Disarray Measurement (CDM) software — a novel tool that can objectively measure neurodegeneration using standard MRI scans. By enabling earlier and more accurate assessments of brain health, the technology is poised to transform how conditions like Alzheimer’s are diagnosed and monitored.
The roll-out follows successful FDA 510(k) clearance and UKCA self-certification, which together provide the regulatory green light for entry into two of the world’s most significant healthcare markets. The company now aims to expand into hospitals, clinics and clinical research organisations that urgently need non-invasive, precision diagnostic tools.
“Neurodegenerative diseases represent a growing public health challenge,” said Dr Steven Chance, CEO and co-founder of OBD. “The support from BGF and our other partners has been instrumental in taking CDM from the lab to the clinic. We’re now in a position to bring hope to millions seeking clarity on their brain health.”
OBD was co-founded in 2019 by Dr Chance, a former Associate Professor of Neuroscience at Oxford University, and Professor Mark Jenkinson, an expert in neuroimaging. The CDM platform builds on decades of scientific research into the structural changes in the brain associated with Alzheimer’s and other neurodegenerative conditions.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
